Peptide Vaccine Candidates for Prostate Cancer Target PSMA and STEAP1 with T Cell Activation
HLA-A*02:01-restricted peptide epitopes from PSMA and STEAP1 induced antigen-specific T cell responses in preclinical assessment, supporting peptide-based immunotherapy development for prostate cancer.
Quick Facts
What This Study Found
HLA-A*02:01-restricted PSMA and STEAP1 epitopes induced antigen-specific T cell responses in preclinical assessment, demonstrating immunogenicity for prostate cancer peptide vaccine development.
Key Numbers
How They Did This
Preclinical evaluation of HLA-A*02:01-restricted peptide epitopes from PSMA and STEAP1, including immunogenicity testing and T cell response characterization.
Why This Research Matters
Prostate cancer is the most common male cancer. Peptide vaccines could provide targeted immunotherapy with minimal side effects.
The Bigger Picture
Peptide-based prostate cancer vaccines could complement existing treatments (surgery, radiation, hormonal) with targeted immune responses.
What This Study Doesn't Tell Us
Preclinical only. HLA-A*02:01 covers ~50% of population. Clinical immunogenicity and anti-tumor efficacy not established.
Questions This Raises
- ?Would these peptides produce clinical anti-tumor responses in prostate cancer patients?
- ?Can the approach be expanded to other HLA types?
- ?Should peptide vaccines be combined with checkpoint inhibitors for prostate cancer?
Trust & Context
- Key Stat:
- Immune T cells activated Peptide fragments from prostate cancer proteins successfully trained immune cells to recognize and attack cancer cells in preclinical testing
- Evidence Grade:
- Preclinical immunogenicity assessment. Standard for early-stage peptide vaccine development.
- Study Age:
- Published in 2025.
- Original Title:
- Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer.
- Published In:
- Drug design, development and therapy, 20, 576346 (2026)
- Authors:
- Huang, Yueting, Yang, Yang(5), Xie, Yanni, Shu, Yue, Yang, Siqi, Long, Xuezhi, Wen, Zhipeng, Duan, Xiaolu, Fu, Li, Gu, Di, Huang, Tuxiong
- Database ID:
- RPEP-15332
Evidence Hierarchy
Frequently Asked Questions
Could a vaccine treat prostate cancer?
Therapeutic peptide vaccines teach the immune system to recognize and attack prostate cancer cells. These PSMA and STEAP1 peptides successfully activated cancer-killing immune cells in lab testing.
Is this available?
Not yet. Preclinical testing proved the peptides activate the right immune cells. Clinical trials in prostate cancer patients are the next step.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15332APA
Huang, Yueting; Yang, Yang; Xie, Yanni; Shu, Yue; Yang, Siqi; Long, Xuezhi; Wen, Zhipeng; Duan, Xiaolu; Fu, Li; Gu, Di; Huang, Tuxiong. (2026). Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer.. Drug design, development and therapy, 20, 576346. https://doi.org/10.2147/DDDT.S576346
MLA
Huang, Yueting, et al. "Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer.." Drug design, 2026. https://doi.org/10.2147/DDDT.S576346
RethinkPeptides
RethinkPeptides Research Database. "Preclinical Assessment of HLA-A*02:01-Restricted PSMA and ST..." RPEP-15332. Retrieved from https://rethinkpeptides.com/research/huang-2026-preclinical-assessment-of-hlaa0201restricted
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.